Drug intelligence / Profile preview

Yixin Pills

Development stage: Unknown
Lead developer: Guangdong Wannianqing Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Yixin Pills (益心丸) is a traditional Chinese medicine (TCM) oral herbal formulation developed and manufactured by Guangdong Wannianqing Pharmaceutical. It is primarily indicated for the treatment of cardiovascular diseases, including coronary heart disease and angina pectoris, particularly in patients presenting with symptoms of Qi deficiency and blood stasis. The formulation is designed to tonify Qi, activate blood circulation, and relieve pain. As a complex herbal product, it contains multiple active constituents, including Ginseng and Toad venom, which work synergistically to improve cardiac function and myocardial blood flow. It is currently approved and marketed in China.

Brand names: 益心丸
Other names: Yixin Wan

Targets

IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on Yixin Pills.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yixin Pills.

Explore the full profile